Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.

Gianluca IacobellisAlexandra C Villasante Fricke

Published in: Journal of the Endocrine Society (2020)

Weekly administration of either GLP-1 receptor agonists semaglutide or dulaglutide causes a rapid, substantial, and dose-dependent reduction in EAT thickness.

Keyphrases

optical coherence tomography
insulin resistance
metabolic syndrome
adipose tissue
weight loss
type diabetes
weight gain
high fat diet induced
fatty acid
body mass index
quantum dots
sensitive detection